Multi-omics analysis reveals the key role of STIL in Li-Fraumeni syndrome and osteosarcoma
Revolutionizing Cancer Research: STIL's Pivotal Role in LFS and Osteosarcoma Progression
Li-Fraumeni syndrome (LFS) and osteosarcoma (OS) pose significant clinical challenges due to their aggressive nature and complex genetic underpinnings. Our multi-omics and in vitro validation study identifies SCL-interrupting locus (STIL) as a pivotal hub linking LFS to OS progression. STIL negatively regulates p53 protein stability, independently of TP53 mutation status, thereby promoting tumorigenesis. Its oncogenic effects are context-dependent, supporting stemness across OS models but more strongly driving invasion and metastasis in TP53-mutant backgrounds. Highly expressed in high-stemness malignant Pro-OSCs, STIL maintains stemness, promotes bone destruction via PTN-NCL and FN1-CD44, and remodels the immune microenvironment through MIF and APP signaling to evade surveillance. WEE1 inhibitors are a potential therapeutic vulnerability in STIL-high OS. This research elucidates STIL's complex regulatory role in p53 stability and its impact on a 'stemness-invasive' phenotype, offering novel biomarkers and intervention targets for precision therapy.
Executive Impact: Key Insights for Enterprise Strategy
Our findings provide crucial insights into the genetic mechanisms of Li-Fraumeni Syndrome and Osteosarcoma, highlighting STIL as a key driver and therapeutic target.
0
LFS carriers’ lifetime cancer risk
0
LFS carriers diagnosed before age 40
0
Higher OS incidence in LFS families
0
Cancer types with upregulated STIL expression
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
STIL
Identified as pivotal hub in LFS-OS link
Enterprise Process Flow
Machine learning identifies STIL
→
scRNA-seq elucidates STIL role
→
In vitro experiments validate STIL role
Poor Prognosis
High STIL correlates with OS metastasis & poor prognosis
| STIL Expression Level | Increased Sensitivity To |
|---|---|
| High STIL |
|
| Low STIL |
|
p53 Stability
STIL negatively regulates p53 protein stability
STIL's Context-Dependent Oncogenicity
STIL's oncogenic effects are highly dependent on the TP53 background. In TP53-wildtype cells (U-2 OS), STIL deficiency triggers cell cycle arrest by restoring p53 function. However, in TP53-mutant cells (143B, mimicking LFS), STIL is essential for maintaining tumor stemness and driving metastasis, activating pathways like PTN-NCL and FN1-CD44. This highlights STIL's adaptive role in promoting tumor progression through different mechanisms depending on TP53 status.
Calculate Your Potential Enterprise ROI
Estimate the financial and efficiency gains your organization could realize by integrating AI-driven insights from our research.
Estimated Annual Savings
$0
Annual Hours Reclaimed
0
Your AI Implementation Roadmap
A strategic overview of how these cutting-edge insights can be integrated into your enterprise operations.
Data Integration & AI Modeling
Combine multi-omics data (microarray, scRNA-seq) for LFS and OS, using WGCNA, LASSO, SVM-RFE, and Random Forest to identify key gene modules and prognostic markers.
Single-Cell Resolution Analysis
Utilize scRNA-seq to map STIL expression across malignant cell trajectories, assess stemness (CytoTRACE), and analyze cell-cell communication networks in the tumor microenvironment (CellChat).
In Vitro Functional Validation
Conduct cell line experiments (SaOS-2, 143B, U-2 OS) including Western blot for p53 stability, colony formation, tumor sphere assays, and wound healing assays to confirm STIL's role in proliferation, stemness, and metastasis.
Translational Biomarker & Therapeutic Targeting
Develop STIL as a potential biomarker for prognosis and identify drug vulnerabilities (e.g., WEE1 inhibitors) based on STIL expression profiles for precision therapy.
Ready to Transform Your Enterprise with AI?
Leverage our expertise to integrate groundbreaking research into actionable AI strategies. Book a free consultation today.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat